Main characteristics of the patients included in the study
| Features . | Prophylaxis group, n = 360* . | Treatment group, n = 238† . |
|---|---|---|
| No. of men | 148 (41.1%) | 118 (49.6%) |
| Age, y, median (range) | 76 (18-96) | 73 (25-95) |
| Active cancer | 59 (16.4%) | 13 (5.5%) |
| Previous heparin treatment‡ | 105 (29.2%) | 90 (37.8%) |
| Daily heparin dosage, IU, median (range) | 15 000 (10 000-20 000) | 25 000 (15 000-40 000) |
| Heparin duration, d, median (range) | 14 (5-45) | 10 (5-32) |
| Features . | Prophylaxis group, n = 360* . | Treatment group, n = 238† . |
|---|---|---|
| No. of men | 148 (41.1%) | 118 (49.6%) |
| Age, y, median (range) | 76 (18-96) | 73 (25-95) |
| Active cancer | 59 (16.4%) | 13 (5.5%) |
| Previous heparin treatment‡ | 105 (29.2%) | 90 (37.8%) |
| Daily heparin dosage, IU, median (range) | 15 000 (10 000-20 000) | 25 000 (15 000-40 000) |
| Heparin duration, d, median (range) | 14 (5-45) | 10 (5-32) |
Indications for heparin administration: immobilization in 160, heart diseases in 75, rheumatic diseases in 55, respiratory failure in 38, infectious diseases in 19, and recent minor surgery in 13.
Indications for heparin administration: venous thromboembolism in 153 (deep vein thrombosis alone or associated with pulmonary embolism in 116, pulmonary embolism alone in 22, superficial thrombophlebitis in 15); arterial thromboembolism in 85 (acute myocardial infarction in 13, unstable angina in 32, arterial embolism in 40).
More than 3 months earlier.